Citations

Clear

634 citation(s) found for "Hall, A".

High‐resolution electrical mapping of porcine gastric slow‐wave propagation from the mucosal surface
Angeli, Timothy R. , Du, Peng , Sathar, Shameer , Asirvatham, S, Farrugia, Gianrico , Windsor, John A. , Cheng, Leo K. , O’Grady, Gregory , Asirvatham, Samuel J. , Paskaranandavadivel, Niranchan , Hall, Andrew , Asirvatham, Samuel J , Angeli-Gordon, Timothy R

Mayo Clinic

Neurogastroenterology & Motility | December 30, 2016 | Volume: 29 | Issue: 5 | Pages: No page available

10.1111/nmo.13010 | PMID 28035728 Get It

AbstractBackgroundGastric motility is coordinated by bioelectrical slow waves, and gastric dysrhythmias are reported in motility disorders. High‐resolution (HR) mapping has advanced the accurate assessment of gastric dysrhythmias, offering promise as a diagnostic technique. However, HR mapping has been restricted to invasive surgical serosal access. This study investigates the feasibility of HR mapping from the gastric mucosal surface.MethodsExperiments were conducted in vivo in 14 weaner pigs. Reference serosal recordings were performed with flexible‐printed‐circuit (FPC) arrays (128‐192 electrodes). Mucosal recordings were performed by two methods: (i) FPC array aligned directly opposite the serosal array, and (ii) cardiac mapping catheter modified for gastric mucosal recordings. Slow‐wave propagation and morphology characteristics were quantified and compared between simultaneous serosal and mucosal recordings.Key ResultsSlow‐wave activity was consistently recorded from the mucosal surface from both electrode arrays. Mucosally recorded slow‐wave propagation was consistent with reference serosal activation pattern, frequency (P≥.3), and velocity (P≥.4). However, mucosally recorded slow‐wave morphology exhibited reduced amplitude (65‐72% reduced, P<.001) and wider downstroke width (18‐31% wider, P≤.02), compared to serosal data. Dysrhythmias were successfully mapped and classified from the mucosal surface, accorded with serosal data, and were consistent with known dysrhythmic mechanisms in the porcine model.Conclusions & InferencesHigh‐resolution gastric electrical mapping was achieved from the mucosal surface, and demonstrated consistent propagation characteristics with serosal data. However, mucosal signal morphology was attenuated, demonstrating necessity for optimized electrode designs and analytical algorithms. This study demonstrates feasibility of endoscopic HR mapping, providing a foundation for advancement of minimally invasive spatiotemporal gastric mapping as a clinical and scientific tool.
Smokeless Tobacco use among United States Air Force Trainees
Linde, Brittany D. , Ebbert, Jon O. , Schroeder, Darrell R. , Hanson, Andrew C. , Talcott, G. Wayne , Klesges, Robert C. , Schroeder, Darrell

Mayo Clinic

Substance Abuse | December 27, 2016 | Volume: 38 | Issue: 3 | Pages: 278-284

10.1080/08897077.2016.1275924 | PMID 28027011 Get It

Background The prevalence of smokeless tobacco use in the United States Air Force (USAF) exceeds civilian use rates. The prevalence and correlates of smokeless tobacco use were assessed and evaluated in a sample of USAF trainees. Methods We conducted a cross-sectional survey of USAF technical training school personnel at Joint Base San Antonio-Lackland and Fort Sam Houston ( N = 14,810). Survey completion rate was 78%. Logistic regression was used to analyze the associations between demographic variables, tobacco use, and social factors for both regular and infrequent smokeless tobacco (e.g., chewing tobacco, snuff) users. Results Overall, 16% of Airmen had ever used smokeless tobacco and 10% regularly used smokeless tobacco. In multivariate analyses, men had greater odds than women of regular smokeless tobacco use (adjusted odds ratio [OR] = 15.2; 95% confidence interval [CI]: 10.8–21.5) and infrequent smokeless tobacco use (adjusted OR = 4.2; 95% CI: 3.1–5.7). Smokeless tobacco use was associated with participation in high school sports (adjusted OR = 1.9; 95% CI: 1.6–2.3 for regular users; adjusted OR = 1.4; 95% CI: 1.1–1.7 for infrequent users), smoking cigarettes (adjusted OR = 4.3; 95% CI: 3.6–5.1 for regular users; adjusted OR = 4.0; 95% CI: 3.2–5.0 for infrequent users), or living with someone who used smokeless tobacco (adjusted OR = 2.2; 95% CI: 1.9–2.6 for regular users; adjusted OR = 1.4; 95% CI: 1.1–1.7 for infrequent users). Black or African Americans were less likely than whites to be regular (adjusted OR = 0.3; 95% CI: 0.1–0.4) or infrequent (adjusted OR = 0.3; 95% CI: 0.2–0.4) users of smokeless tobacco. Conclusions Smokeless tobacco use among incoming Air Force recruits is common and negatively impacts the Air Force's goal to be tobacco-free. Understanding sociodemographic characteristics perpetuating smokeless tobacco use in the Air Force population can inform the development of health promotion interventions.
Pediatric Sleep Duration Consensus Statement: A Step Forward
Paruthi, Shalini, Brooks, Lee J., D’Ambrosio, Carolyn, Hall, Wendy A. , Kotagal, Suresh , Lloyd, Robin M. , Malow, Beth A. , Nichols, Cynthia , Quan, Stuart F. , Rosen, Carol L. , Troester, Matthew M., Wise, Merrill S. , Maski, Kiran

Mayo Clinic

Journal of Clinical Sleep Medicine | December 14, 2016 | Volume: 12 | Issue: 12 | Pages: 1705-1706

10.5664/jcsm.6368 | PMID 27855732 Get It

Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21
Hamdi, Yosr , Collaborators, NBCS, Soucy, Penny, Adoue, Véronique , Michailidou, Kyriaki , Canisius, Sander , Lemaçon, Audrey , Droit, Arnaud , Andrulis, Irene L. , Baynes, Caroline, Blomqvist, Carl , Bogdanova, Natalia , Bojesen, Stig E. , Bolla, Manjeet K. , Børresen‐Dale, Anne‐Lise , Brand, Judith S. , Brauch, Hiltrud , Brenner, Hermann , Burwinkel, Barbara , Chang‐Claude, Jenny , Darabi, Hatef, Devilee, Peter , Dörk, Thilo , Eriksson, Mikael , Fasching, Peter A. , Figueroa, Jonine D. , Flyger, Henrik, García‐Closas, Montserrat , Goldberg, Mark S. , González‐Neira, Anna , Grenaker-Alnæs, Grethe Irene, Guénel, Pascal , Haeberle, Lothar, Haiman, Christopher A., Hamann, Ute, Hallberg, Emily, Hooning, Maartje J. , Jakubowska, Anna , Jones, Michael E. , Kabisch, Maria, Kataja, Vesa , Lambrechts, Diether , Lindblom, Annika , Lubiński, Jan , Mannermaa, Arto, Maranian, Mel, Margolin, Sara , Marme, Frederik, Neven, Patrick , Olswold, Curtis, Peto, Julian, Plaseska‐Karanfilska, Dijana , Pylkäs, Katri , Radice, Paolo , Sawyer, Elinor J. , Schmidt, Marjanka K. , Shu, Xiao-Ou , Southey, Melissa C. , Swerdlow, Anthony J. , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Torres, Diana , Truong, Thérèse , Vachon, Celine M. , Ouweland, Ans M.W. van den, Wang, Qin , Winqvist, Robert , Investigators, kConFab AOCS, Benı́tez, Javier , Chenevix‐Trench, Georgia , Dunning, Alison M. , Kristensen, Vessela N. , Easton, Douglas F. , Pastinen, Tomi , Simard, Jacques , Durocher, Francine , Zheng, Wei , Thorne, Heather , Lambrechts, Diether , Vachon, Celine, Collaborators, NBCS, Anton‐Culver, Hoda , Arndt, Volker , Bonanni, Bernardo , Broeks, Annegien , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Dennis, Joe , dos‐Santos‐Silva, Isabel , Eriksson, Mikael , Giles, Graham G. , Hooning, Maartje J. , Hopper, John L. , Marchand, Loı̈c Le , Mannermaa, Arto , Milne, Roger L. , Neuhausen, Susan L. , Nevanlinna, Heli , Rudolph, Anja , Vachon, Celine M. , Zheng, Wei , Pharoah, Paul D.P. , Hall, Per N , Nord, Silje , Dörk, Thilo , Lambrechts, Diether , Swerdlow, Anthony J , Radice, Paolo , Southey, Melissa C , Dunning, Alison M , Jakubowska, Anna , Jones, Michael E , Lambrechts, Diether , Brenner, Hermann , Guénel, Pascal , Torres, Diana , García-Closas, Montserrat , Schmidt, Marjanka K , Michailidou, Kyriaki , Bogdanova, Natalia V , Benitez, Javier , Simard, Jacques , Chenevix-Trench, Georgia , Zheng, Wei , Figueroa, Jonine D , Pylkäs, Katri , Devilee, Peter , Lubinski, Jan , Bojesen, Stig E , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Droit, Arnaud

Mayo Clinic

Oncotarget | November 28, 2016 | Volume: 7 | Issue: 49 | Pages: 80140-80163

10.18632/oncotarget.12818 | PMID 27792995 Get It

Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
Lista, Simone , Vanderstichele, Hugo, Posner, Holly, Hall, James , Johnson, Leigh , Fong, Y L, Luthman, Johan, Jeromin, Andreas, Batrla‐Utermann, Richard, Villarreal, Alcibiades E. , Britton, Gabrielle B. , Snyder, Peter J. , Henriksen, Kim , Grammas, Paula , Gupta, Veer Bala , Martins, Ralph N. , Hampel, Harald , Area, Biofluid Based Biomarker Professional Interest, O’Bryant, Sid E. , Mielke, Michelle M. , Rissman, Robert A. , Zetterberg, Henrik , Lewczuk, Piotr , Area, Biofluid Based Biomarker Professional Interest

Mayo Clinic

Alzheimer's & Dementia | November 18, 2016 | Volume: 13 | Issue: 1 | Pages: 45-58

10.1016/j.jalz.2016.09.014 | PMID 27870940 Get It

AbstractThe last decade has seen a substantial increase in research focused on the identification of blood‐based biomarkers that have utility in Alzheimer's disease (AD). Blood‐based biomarkers have significant advantages of being time‐ and cost‐efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood‐based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public‐private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
Evaluating the utility of serological testing in laryngotracheal stenosis
Hall, Stuart R., Meratı, Albert L., Mayerhoff, Ross , Hall, S Ryan, Allen, Clint T , Mayerhoff, Ross

Mayo Clinic

The Laryngoscope | November 16, 2016 | Volume: 127 | Issue: 6 | Pages: 1408-1412

10.1002/lary.26385 | PMID 27861923 Get It

Consensus Statement of the American Academy of Sleep Medicine on the Recommended Amount of Sleep for Healthy Children: Methodology and Discussion
Paruthi, Shalini, Brooks, Lee J., D’Ambrosio, Carolyn, Hall, Wendy A. , Kotagal, Suresh , Lloyd, Robin M. , Malow, Beth A. , Nichols, Cynthia , Quan, Stuart F. , Rosen, Carol L. , Troester, Matthew M., Wise, Merrill S. , Maski, Kiran

Mayo Clinic

Journal of Clinical Sleep Medicine | November 14, 2016 | Volume: 12 | Issue: 11 | Pages: 1549-1561

10.5664/jcsm.6288 | PMID 27707447 Get It

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction
Canetta, Pietro A. , Appel, Gerald B., Nath, Karl A. , Sethi, Sanjeev , Tumlin, James A., Mehta, Kshama , Hogan, Marie C. , Julian, Bruce A. , Brown, Rhubell, Knoppová, Barbora , Hall, Stacy, Enders, Felicity T, Lafayette, Richard , Rovin, Brad H. , Novák, Jan , Erickson, Stephen W. , Leung, Nelson , Enders, Felicity , Fervenza, Fernando C. , Hogan, Marie C

Mayo Clinic

Journal of the American Society of Nephrology | November 7, 2016 | Volume: 28 | Issue: 4 | Pages: 1306-1313

10.1681/asn.2016060640 | PMID 27821627 Get It

IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody–producing B cells potentially offers a new therapy. In this open label, multicenter study conducted over 1-year follow-up, we randomized 34 adult patients with biopsy–proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin–converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR<90 ml/min per 1.73 m 2 , to receive standard therapy or rituximab with standard therapy. Primary outcome measures included change in proteinuria and change in eGFR. Median baseline serum creatinine level (range) was 1.4 (0.8–2.4) mg/dl, and proteinuria was 2.1 (0.6–5.3) g/d. Treatment with rituximab depleted B cells and was well tolerated. eGFR did not change in either group. Rituximab did not alter the level of proteinuria compared with that at baseline or in the control group; three patients in each group had ≥50% reduction in level of proteinuria. Serum levels of galactose-deficient IgA1 or antibodies against galactose-deficient IgA1 did not change. In this trial, rituximab therapy did not significantly improve renal function or proteinuria assessed over 1 year. Although rituximab effectively depleted B cells, it failed to reduce serum levels of galactose-deficient IgA1 and antigalactose–deficient IgA1 antibodies. Lack of efficacy of rituximab, at least at this stage and severity of IgA nephropathy, may reflect a failure of rituximab to reduce levels of specific antibodies assigned salient pathogenetic roles in IgA nephropathy.
Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III
Hujer, Andrea M. , Jiang, Hongyu , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Tran, Thuy Tien T., Higgins, Paul G. , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Sampath, Rangarajan , Marzan, Christine, Fowler, Vance G. , Chambers, Henry F. , Sampath, Rangarajan , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Seifert, Harald , Kreiswirth, Barry N , Jacobs, Michael R. , Chen, Liang , Hall, Thomas A. , Fowler, Vance G. , Bonomo, Robert A. , Patel, Robin , Evans, Scott R

Mayo Clinic

Journal of Clinical Microbiology | October 26, 2016 | Volume: 55 | Issue: 1 | Pages: 134-144

10.1128/jcm.01524-16 | PMID 27795336 Get It

ABSTRACT The widespread dissemination of carbapenem-resistant Acinetobacter spp. has created significant therapeutic challenges. At present, rapid molecular diagnostics (RMDs) that can identify this phenotype are not commercially available. Two RMD platforms, PCR combined with electrospray ionization mass spectrometry (PCR/ESI-MS) and molecular beacons (MB), for detecting genes conferring resistance/susceptibility to carbapenems in Acinetobacter spp. were evaluated. An archived collection of 200 clinical Acinetobacter sp. isolates was tested. Predictive values for susceptibility and resistance were estimated as a function of susceptibility prevalence and were based on the absence or presence of beta-lactamase ( bla ) NDM, VIM, IMP, KPC, and OXA carbapenemase genes (e.g., bla OXA-23 , bla OXA-24/40 , and bla OXA-58 found in this study) against the reference standard of MIC determinations. According to the interpretation of MICs, 49% ( n = 98) of the isolates were carbapenem resistant (as defined by either resistance or intermediate resistance to imipenem). The susceptibility sensitivities (95% confidence interval [CI]) for imipenem were 82% (74%, 89%) and 92% (85%, 97%) for PCR/ESI-MS and MB, respectively. Resistance sensitivities (95% CI) for imipenem were 95% (88%, 98%) and 88% (80%, 94%) for PCR/ESI-MS and MB, respectively. PRIMERS III establishes that RMDs can discriminate between carbapenem resistance and susceptibility in Acinetobacter spp. In the context of a known prevalence of resistance, SPVs and RPVs can inform clinicians regarding the best choice for empiric antimicrobial therapy against this multidrug-resistant pathogen.
Abstract B41: Cell-contact dependent epithelial-stromal cross talk, including a modulation of stromal PDGFR expression, drives the progression of early-stage breast cancer lesions
Paulsson, Janna, Jin, Shaobo , Roswall, Pernilla, Johanna, Andrea, Frings, Oliver , Warnberg, Fredrick, Johansson, Hemming , Östman, Arne , Strell, Carina , Mezheyeuski, Artur , Jirström, Karin , Pietras, Kristian , Hall, Per N , Lendahl, Urban , Betsholtz, Christer , Radisky, Derek C.

Mayo Clinic

Cancer Research | October 24, 2016 | Volume: 76 | Issue: 15_Supplement | Pages: B41-B41

10.1158/1538-7445.tme16-b41 Get It

Abstract We have investigated the distribution of PDGFR-a and -b in the stroma of normal breast tissue, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) by immunohistochemistry. Both receptors were expressed by fibroblasts of normal breast tissue. While the PDGFRb remained high during cancer progression, the PDGFRa was lost in most of the DCIS samples and not detectable in IDC. The patient group with PDGFRa(low)/PDGFRb(high) fibroblasts had the highest risk for local recurrences or metastasis. The characteristic loss of stromal PDGFRa expression was also observed in the PyMT mouse breast cancer model. In vitro co-culture experiments confirmed a tumor cell-induced differentiation of fibroblasts, resulting in a fibroblast population marked by PDGFRa(low)/PDGFRb(high) expression. We could identify the interaction of Jagged-1 expressed by the tumor cells with Notch-2 expressed on the fibroblasts, as an essential activator of TGFb signaling in fibroblasts. Gene expression analysis and reporter-gene assays of sorted cells from co-cultures revealed, that fibroblasts switch from a more anti-tumorigenic signaling (expression of BMPs and Wnt antagonists) towards a pro-tumorigenic signaling (expression of BMP inhibitors, TGFb and Wnt ligands). Co-cultured tumor cells show an increased migratory activity and the induction of a mesenchymal phenotype. Inhibition of Notch or TGF signaling in fibroblasts could block these phenotypes. To investigate the impact of fibroblasts on the progression of DCIS to IDC, a DCIS xenograft model was used. Co-injection of MCF10.DCIS cells with human breast fibroblasts, expressing both PDGFRs, into the mouse mammary fat pad resulted in an earlier tumor take with faster tumor growth. The corresponding co-injection experiments with fibroblast and tumor cells, that were depleted of Notch2 respectively Jagged-1 expression by CRISPR/CAS technology is currently ongoing. Collectively the study identifies a potentially druggable paracrine cross-talk between epithelial and stromal cells, which promotes DCIS progression and involves a Notch mediated up-regulation of TGFb signaling. The study also suggests that loss of PDGFRa marks a subset of fibroblasts with specific tumor-promoting activities. Citation Format: Carina Strell, Janna Paulsson, Artur Mezheyeuski, Shao-Bo Jin, Pernilla Roswall, Johanna Andrea, Oliver Frings, Fredrick Warnberg, Hemming Johansson, Karin Jirstrom, Kristian Pietras, Per Hall, Urban Lendahl, Christer Betsholtz, Derek C. Radisky, Arne Ostman. Cell-contact dependent epithelial-stromal cross talk, including a modulation of stromal PDGFR expression, drives the progression of early-stage breast cancer lesions. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr B41.